Alpha-1 Antitrypsin Deficiency Treatment Market By Disease Manifestation (Pulmonary AATD, AATD-Associated Liver Disease); By Treatment Setting (Infusion and Specialist Clinics, Home-Based Infusion, Transplant and Tertiary Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Alpha-1 Antitrypsin Deficiency Treatment Market Size and How Is the Therapeutic Landscape Changing?

The Global Alpha-1 Antitrypsin Deficiency Treatment Market was valued at USD 1.68 billion in 2025 and is projected to reach USD 2.73 billion by 2032, expanding at a CAGR of 7.2% during 2026-2032, according to Strategic Market Research.

 

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder creating a specialized therapeutics market focused on protecting lung function and addressing disease progression. Severe PI*ZZ genotype patients represent the primary commercial population, with approximately 235,000 individuals identified globally across 48 countries and nearly 100,000 estimated patients in the U.S. However, limited diagnosis remains a major market barrier, with only around 10,000 U.S. patients recognized.

 

The Alpha-1 antitrypsin deficiency (AATD) therapeutics market is transitioning from plasma-derived augmentation therapy toward advanced disease-modifying platforms targeting both lung protection and underlying genetic mechanisms. Sanofi is developing efdalorprin alfa, a recombinant AAT fusion protein technology designed to improve dosing convenience and maintain functional AAT levels. Arrowhead Pharmaceuticals applies RNA interference (RNAi) technology to suppress mutant Z-AAT protein production and reduce liver damage risk. Intellia Therapeutics explores CRISPR-based gene editing platforms for genetic correction, while emerging companies are advancing inhaled AAT delivery systems, neutrophil elastase inhibitors, and protein-stabilizing technologies to expand treatment options beyond conventional augmentation therapy.

 

Alpha-1 antitrypsin deficiency (AATD) represents an underdiagnosed rare disease population with significant unmet treatment potential. In the United States, AATD affects approximately 1 in 3,000–5,000 individuals, with 70,000–100,000 patients estimated to have the severe PI*ZZ genotype, but only around 7,000–10,000 diagnosed cases. Globally, 1.1–3.4 million individuals are estimated to have severe deficiency variants, while diagnosis rates remain below 1% in many regions. The global carrier population exceeds 116 million people, creating a broad genetic screening opportunity.

 

Alpha-1 Antitrypsin Deficiency Treatment Market Key Report Takeaways

Disease Manifestation

Subsegment	2025 Market Share	2025 Market Size	2032 Forecast	CAGR (2026–2032)	Market Insight
Pulmonary AATD	82.0%	USD 1.38 Billion	USD 2.11 Billion	6.3%	Remains the dominant commercial segment because current disease-specific augmentation therapy is primarily used for pulmonary AATD with clinically evident emphysema.
AATD-Associated Liver Disease	18.0%	USD 0.30 Billion	USD 0.62 Billion	10.7%	Expands faster as the treatment landscape moves beyond supportive care toward liver-directed therapies such as RNA-interference programs.

 

Treatment Setting

Subsegment	2025 Market Share	2025 Market Size	2032 Forecast	CAGR (2026–2032)	Market Insight
Infusion and Specialist Clinics	48.0%	USD 0.81 Billion	USD 1.19 Billion	5.7%	Remain the largest revenue setting because specialist assessment, supervised infusion, monitoring, and complex patient management are concentrated in these facilities.
Home-Based Infusion	38.0%	USD 0.64 Billion	USD 1.13 Billion	8.5%	Expands faster as chronic weekly augmentation increasingly shifts toward home administration and more flexible treatment delivery.
Transplant and Tertiary Centers	14.0%	USD 0.24 Billion	USD 0.41 Billion	8.3%	Serve smaller but high-intensity patient populations progressing to advanced respiratory failure, cirrhosis, or transplantation.

 

Geography

Region	2025 Market Share	2025 Market Size	2032 Forecast	CAGR (2026–2032)	Market Insight
North America	60.0%	USD 1.01 Billion	USD 1.56 Billion	6.4%	Leads through established augmentation therapy, specialty infusion infrastructure, payer pathways, and a comparatively developed diagnosed-patient base.
Europe	26.0%	USD 0.44 Billion	USD 0.72 Billion	7.5%	Has a substantial severe-genotype population, although treatment penetration varies considerably because reimbursement differs across countries.
Asia-Pacific	8.0%	USD 0.13 Billion	USD 0.27 Billion	10.5%	Records the fastest regional expansion as specialist recognition, genetic testing, and access to disease-specific therapies improve from a smaller base.
Latin America	4.0%	USD 0.07 Billion	USD 0.12 Billion	8.5%	Development is tied mainly to diagnosis, specialist networks, reimbursement, and reliable distribution of chronic AATD therapies.
Middle East & Africa	2.0%	USD 0.03 Billion	USD 0.06 Billion	8.6%	Remains a country-specific rare-disease opportunity shaped by severe-genotype prevalence, diagnostic infrastructure, and treatment access.

 

Diagnosis-to-Treatment Conversion: The Commercial Funnel Behind AATD Revenue

The commercial funnel begins with case finding, not prevalence. The 2025 AnnalsATS review estimated that only about one in ten Americans with severe PI*ZZ AATD has been recognized, and diagnostic delays of roughly five to eight years remain persistent. The 2025 Canadian Thoracic Society guideline recommends testing all individuals with COPD at diagnosis, adults with persistent airflow obstruction after adult-onset asthma, and people with unexplained bronchiectasis. The 2026 Spanish guideline similarly recommends broader targeted detection and a two-step diagnostic approach combining serum AAT measurement with genotype or phenotype characterization when appropriate. [2,4,5]

Diagnosis alone does not create a treated patient. The 2025 Canadian guideline conditionally recommends augmentation for never- or former-smokers with COPD, documented emphysema, FEV1 below 80% predicted, a severe deficiency genotype and functional AAT below 11 micromol/L, in addition to optimal COPD therapy. The 2026 Spanish update uses a similarly restrictive framework based on severe documented deficiency, AAT below 11 micromol/L, CT-confirmed emphysema, impaired pulmonary function and absence of active smoking. Current U.S. payer criteria also require clinically evident emphysema and pretreatment AAT below 11 micromol/L, with some plans applying FEV1 and product-preference requirements. [4,5,28]

Kamada provides a direct commercial example of this linkage. Its 2025 filing reported USD 19.4 million in GLASSIA sales outside the United States and Canada, compared with USD 15.2 million in 2024, and attributed the increase mainly to newly diagnosed AATD patients receiving treatment. This is more commercially informative than prevalence alone because it shows case identification translating into realized product sales. [27]

 

Site-of-Care Economics: Home Infusion, Persistence and Cost in the AATD Treatment Market

Weekly IV treatment makes site of care economically important. In an AlphaNet survey of 5,266 augmentation users, 60.2% received infusions at home from healthcare providers, 30.6% used infusion clinics and 8.1% self-infused. These patient-use proportions should not be confused with SMR revenue shares by treatment setting: clinics and tertiary centers can carry greater revenue intensity because they include specialist evaluation, supervised infusion, monitoring and advanced care, while home treatment accounts for a larger proportion of patient episodes. [11]

On an SMR revenue basis, infusion and specialist clinics represented 48.0% of the market in 2025, equal to USD 0.81 billion, while home-based infusion accounted for 38.0% or USD 0.64 billion and transplant/tertiary centers represented 14.0% or USD 0.24 billion. Home-based infusion is projected to expand faster than clinic-based treatment through 2032 because chronic patients increasingly value reduced travel and greater scheduling flexibility, while the underlying drug remains a recurring weekly therapy.

Persistence creates another point of revenue leakage. A 2026 U.S. claims analysis identified 159 new Alpha1-PI users; 64.8% met the study's adherence threshold, only 46.5% persisted with their original therapy for 12 months, and 28.3% discontinued before starting another augmentation product. Claims data cannot establish why patients switched or stopped, but they show why product convenience, specialty support, payer policy and infusion logistics influence realized revenue after the initial prescription. [12]

Cost reinforces that sensitivity. A U.S. claims study expressed in 2017 dollars found annual medical costs of USD 127,537 among augmentation users versus USD 15,874 among non-users, with augmentation accounting for 75.3% of the difference. These are historical cost data rather than 2026 pricing, but they explain why payers require tight eligibility criteria and why future subcutaneous or longer-interval therapies will be judged on total treatment economics rather than convenience alone. [13]

 

AATD-Associated Liver Disease: The Next Incremental Therapeutic Revenue Pool

Pulmonary and hepatic AATD create different commercial treatment problems. Lung disease is driven largely by insufficient functional AAT protection, which provides the rationale for replacement therapy. Liver disease is caused by intracellular accumulation and polymerization of mutant Z-AAT in hepatocytes. Conventional augmentation increases circulating AAT but does not remove the toxic hepatic protein, leaving liver disease without an established disease-specific drug treatment. [15]

SMR estimates that pulmonary AATD represented 82.0% of the 2025 market, equal to USD 1.38 billion, and will reach USD 2.11 billion by 2032 at a CAGR of 6.3%. AATD-associated liver disease accounted for 18.0% or USD 0.30 billion in 2025 and is projected to reach USD 0.62 billion by 2032 at a faster CAGR of 10.7%. The liver segment grows from a smaller base because current spending is dominated by supportive management and advanced organ care, while late-stage drug development could create a new pharmacological revenue pool.

A Swedish population-based cohort of 2,286 diagnosed individuals illustrates the long-term organ burden. Ten-year cumulative incidence was 4.14% for lung transplantation and 1.69% for liver transplantation, and only about 20% of patients were estimated to be alive without lung disease or liver cirrhosis 20 years after diagnosis. These figures are not a direct market-size input, but they show why multi-organ treatment is relevant to lifetime value and specialist-care utilization. [14]

Fazirsiran is the most advanced liver-directed program. The RNA-interference therapy reduces production of mutant Z-AAT by degrading its messenger RNA. In the Phase II SEQUOIA study, serum Z-AAT fell by 61%, 83% and 94% at Week 16 across the 25 mg, 100 mg and 200 mg groups, while median liver Z-AAT fell by 93% at follow-up biopsy. Takeda's Phase III NCT05677971 study remained recruiting in its May 13, 2026 update and is evaluating histologic fibrosis improvement at Week 106 in patients with F2-F4 disease. If successful, fazirsiran would create a drug-treated liver segment rather than simply shifting share within pulmonary augmentation. [15,16]

 

Beyond Weekly Infusion: Subcutaneous, Recombinant, RNA and Gene-Editing Competition

The next competitive cycle is organized around treatment burden and disease biology rather than another weekly plasma product. Grifols began the Phase III SWIFT-SC trial in June 2026 to compare weekly subcutaneous Alpha1-PI 15% with corresponding standard IV doses. The program is a lifecycle-extension strategy rather than a new biological mechanism, but successful pharmacokinetic non-inferiority could give the incumbent franchise a more flexible administration option and protect share as other modalities advance. [10]

Sanofi is testing a different replacement model with efdoralprin alfa, a recombinant AAT-Fc fusion protein intended to sustain functional AAT for three or four weeks. In the 97-patient Phase II ElevAATe study, mean change in functional-AAT trough concentration at Week 32 was 24.1 micromol/L with three-week dosing and 16.8 micromol/L with four-week dosing versus 7.6 micromol/L with weekly plasma-derived therapy. These are pharmacologic rather than long-term clinical-outcome endpoints, but the program directly challenges weekly dosing and plasma dependence. [17]

Beam Therapeutics is pursuing one-time genetic correction with BEAM-302. The in-vivo base editor is designed to correct the PiZ mutation in liver cells, increase functional M-AAT and reduce mutant Z-AAT. Beam announced the first patient dosed in its global pivotal cohort on August 4, 2026 after earlier Phase I/II results supported selection of a 60 mg dose. If durability and safety are confirmed, BEAM-302 could compete across both pulmonary and hepatic value pools rather than only against another augmentation brand. [18]

Wave Life Sciences is taking a reversible RNA-editing approach with WVE-006. In May 2026, the company reported that 200 mg every two weeks generated wild-type M-AAT representing 64% of total AAT, reduced Z-AAT by 71%, and produced total AAT of 11.9 micromol/L; a 400 mg monthly regimen produced 13.6 micromol/L total AAT. The commercial proposition is a subcutaneous, repeat-dose genetic medicine that may sit between lifelong protein replacement and permanent DNA editing. [19]

Earlier-stage competition is also becoming more crowded. AIRNA dosed the first patient in its Phase I AIR-001 RNA-editing study in April 2026 and reported FDA Orphan Drug Designation. Krystal Biotech's recruiting Phase I Serpentine-1 study is evaluating KB408, a nebulized non-integrating HSV-1-derived vector designed to deliver functional SERPINA1 directly to the airways. Korro Bio selected KRRO-111 as a preclinical AATD development candidate in May 2026 using a GalNAc-conjugated RNA-editing approach. These programs are too early to model as current revenue, but they widen the range of possible future treatment architectures. [20,21,24]

 

Geographic Revenue Conversion: Where AATD Disease Burden Becomes Treatment Sales

North America accounted for an SMR-estimated 60.0% of the market, representing USD 1.01 billion in 2025, and is projected to reach USD 1.56 billion by 2032 at a CAGR of 6.4%. The United States combines multiple FDA-listed augmentation products, specialty infusion infrastructure, payer pathways and the largest established commercial treatment base. Yet the roughly 100,000 estimated PI*ZZ population compared with only about 10,000 recognized patients leaves substantial diagnosis-related headroom. Canada has also broadened access through Canadian Blood Services, which added GLASSIA to its Plasma Protein and Related Products formulary outside Quebec and made it available for ordering from February 29, 2024. [1,2,25]

Europe represented 26.0% of the market, equal to USD 0.44 billion in 2025, and is projected to reach USD 0.72 billion by 2032 at a CAGR of 7.5%. Europe accounted for about half of the modeled worldwide PI*ZZ population in the 2023 epidemiological analysis, but treatment conversion varies sharply by country. Respreeza has a European regulatory platform, yet NICE terminated its 2024 appraisal after CSL Behring stated that it did not intend to launch the product in England and Wales because it could not offer a price meeting the relevant cost-effectiveness threshold. This illustrates why genetic burden does not automatically translate into commercial revenue. [3,26]

Asia-Pacific accounted for 8.0% of the market, representing USD 0.13 billion in 2025, and is projected to reach USD 0.27 billion by 2032 at a CAGR of 10.5%. The epidemiological burden is uneven: Asia represented about 9% of the modeled worldwide PI*ZZ population and Australasia another 3%. Australia and New Zealand therefore offer a more established genetically relevant base than many Asian countries, while future treatment growth across the wider region depends on testing, specialist recognition, reimbursement and entry of easier-to-administer therapies. [3]

Latin America represented 4.0% of the market, equal to USD 0.07 billion in 2025, and is projected to reach USD 0.12 billion by 2032 at a CAGR of 8.5%. Argentina is already an important international GLASSIA market for Kamada, and the company's 2025 filing linked higher ex-U.S./Canada sales to newly diagnosed patients entering therapy. Regional expansion is therefore more likely to come from case identification, specialist networks and reliable distribution than from broad population-level utilization. [27]

The Middle East & Africa accounted for 2.0% of the market, representing USD 0.03 billion in 2025, and is projected to reach USD 0.06 billion by 2032 at a CAGR of 8.6%. Africa represented only about 1% of the modeled worldwide PI*ZZ population, while selected Middle Eastern populations show more meaningful severe-genotype prevalence. The commercial opportunity is therefore country-specific and dependent on genetic epidemiology, access to specialist diagnosis and the ability to fund rare-disease treatment. [3]

 

Competitive Reset: Plasma Franchises Versus RNA and Gene Editing

Competition now spans two very different business models. Established plasma companies compete on product familiarity, infusion services, diagnosis support, payer access and manufacturing scale. New biotechnology entrants compete on route, treatment interval, ability to address liver disease, durability and the possibility of correcting the SERPINA1 defect rather than repeatedly replacing protein. This makes the market less about brand switching within IV augmentation and more about whether new modalities can alter lifetime treatment economics.

Grifols

Grifols' Alpha-1 franchise is centered on Prolastin-C and a large testing/patient-support infrastructure. The company reported approximately EUR 700-750 million in trailing-12-month Alpha-1 revenue at Q3 2025 and estimated about 70% market share. SPARTA is intended to strengthen outcomes evidence, while SWIFT-SC extends the franchise toward subcutaneous delivery. Grifols is therefore both the incumbent most exposed to disruptive modalities and the company with the clearest lifecycle-management response. [8,9,10]

Takeda and Kamada

Takeda commercializes GLASSIA in major territories and sponsors the Phase III fazirsiran program for AATD-associated liver disease, giving it exposure to both the existing replacement market and a potential new hepatic drug segment. Kamada remains an important GLASSIA manufacturer and international commercial partner. Its 2025 sales data show that newly diagnosed patients can produce measurable product growth, while the December 2025 InnovAATe discontinuation also demonstrates the clinical risk of attempting to shift AAT delivery to a new route without sufficiently differentiated efficacy. [16,22,27]

CSL Behring

CSL Behring competes through Zemaira in the United States and Respreeza in Europe. The franchise benefits from the RAPID clinical evidence around CT lung-density preservation, but its European experience also shows the limits of approval without commercially viable reimbursement. NICE's terminated appraisal is a useful reminder that plasma manufacturing complexity and high treatment cost can constrain penetration even in regions with substantial genetic prevalence. [6,26]

Sanofi

Sanofi is developing efdoralprin alfa as a recombinant alternative to weekly plasma-derived augmentation. The AAT-Fc fusion protein is designed to maintain functional AAT with dosing every three or four weeks. Its commercial differentiation rests on longer intervals and recombinant supply rather than on permanent genetic correction. The next development step will need to translate strong pharmacokinetic results into clinically persuasive outcomes. [17]

Beam Therapeutics

Beam Therapeutics is developing BEAM-302 as a one-time in-vivo base-editing therapy designed to correct the PiZ mutation in hepatocytes. The first patient entered the global pivotal cohort in August 2026. If pivotal development confirms durable M-AAT restoration, Z-AAT reduction and an acceptable safety profile, BEAM-302 could compete across both lung and liver manifestations and materially alter the lifetime-revenue model of AATD treatment. [18]

Wave Life Sciences

Wave Life Sciences is developing WVE-006 as a repeat-dose, subcutaneous RNA-editing therapy. The approach aims to generate wild-type M-AAT and reduce harmful Z-AAT without permanently changing DNA. Its positioning sits between chronic replacement and one-time gene editing, potentially offering titratable treatment with less frequent administration if the biological effects observed in Phase Ib/IIa development translate into clinical benefit. [19]

Emerging Clinical and Preclinical Entrants

AIRNA's AIR-001 entered Phase I in April 2026 using RNA editing; Krystal Biotech's KB408 is in a recruiting Phase I study using nebulized HSV-1 vector delivery of functional SERPINA1 to the airways; and Korro Bio selected the preclinical RNA-editing candidate KRRO-111 in May 2026. These programs are earlier than Beam, Wave, Sanofi and fazirsiran, but they broaden the competitive technology map and increase the probability that future AATD treatment will include multiple modalities rather than a single replacement paradigm. [20,21,24]

 

Analyst Commentary : The Next Frontier in AATD: From Protein Replacement to Genetic Correction

The AATD market is shifting from weekly protein replacement toward therapies that address the underlying disease. Different technologies may lead in pulmonary and liver disease.

Fazirsiran has the clearest opportunity to create a new liver-treatment market because it reduces harmful Z-AAT, with Phase III testing whether this improves fibrosis. In pulmonary AATD, Sanofi’s efdoralprin alfa is a strong near-term challenger to weekly plasma-derived therapy. Its recombinant AAT-Fc design could allow dosing every three to four weeks, reducing treatment burden without the risks and uncertainty of permanent gene editing.

BEAM-302 has the greatest long-term disruptive potential. Its in-vivo base-editing approach aims to correct the PiZ mutation, increase functional M-AAT and reduce toxic Z-AAT with a one-time treatment. If it demonstrates durable efficacy and acceptable safety, it could treat both lung and liver disease and shift the market from recurring therapy to high-value genetic treatment.

WVE-006 offers a potential middle ground: reversible RNA editing that produces functional M-AAT and reduces Z-AAT, potentially with monthly subcutaneous dosing. Grifols’ subcutaneous Alpha1-PI would improve convenience but remains a weekly replacement therapy and is therefore more evolutionary than transformational.

Through 2032, competition will likely develop across three waves: improved augmentation, RNA-based disease modification and genetic correction. Fazirsiran may lead in liver disease, efdoralprin alfa in near-term pulmonary convenience, WVE-006 in reversible RNA editing and BEAM-302 in long-term disease correction. The leading therapy will need to improve functional AAT, reduce harmful Z-AAT, lower treatment burden and generate evidence strong enough to support premium reimbursement.

 

Alpha-1 Antitrypsin Deficiency Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 1.68 Billion
Revenue Forecast in 2032	USD 2.73 Billion
Overall Growth Rate	CAGR of 7.2% during 2026–2032
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion
Segmentation	By Disease Manifestation, Treatment Setting, and Geography
By Disease Manifestation	Pulmonary AATD; AATD-Associated Liver Disease
By Treatment Setting	Infusion and Specialist Clinics; Home-Based Infusion; Transplant and Tertiary Centers
By Region	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Country Scope	United States, Canada, Mexico, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Brazil, Argentina, GCC Countries, South Africa, and Rest of World
Market Drivers	Underdiagnosed severe AATD population, expansion of targeted genetic testing, growth of home-based infusion, development of liver-directed therapies, longer-interval recombinant augmentation, and advancement of RNA-editing and gene-editing platforms
Customization Option	Available upon request